3.04 Listener Questions & MedTwitter and Risk-Benefit Profile of Ramucirumab with Dr. Bishal Gyawali

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7 • 789 Ratings

🗓️ 24 July 2020

⏱️ 92 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials". Ramucirumab: doi.org/10.1016/j.eclinm.2020.100458 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome. I'm Dr. Vinay Prasad. I'm a hematologist, oncologist, and I'm associate professor of medicine at the University of California, San Francisco. In my professional life, I see patients, I teach trainees, and I do research in health care policy. This is plenary session.
0:22.9	Plenary session is a podcast at the intersection of medicine, oncology, and health policy,
0:27.6	and you're listening to Season 3. On this week's episode, first up, listener questions. You
0:35.0	won't want to miss this. Then I'm joined by Dr. Bish Gaywally, and we're going to talk about recent events in the news.
0:41.2	So we've got quite a show in store for you.
0:43.3	Stay tuned.
0:45.1	If you like this podcast and want more content, follow me on Twitter at Viprasad MDMPH.
0:51.5	Check out the YouTube channel, Vinay Prasad, MDMPH.
0:55.7	Patreon backers will get access to the slides for lectures I give on plenary session.
1:00.3	Want to hear from us? Email us your question at plenary session podcast at gmail.com.
1:08.9	First up, listener questions.
1:17.2	The first listener question comes from Dr. Sophie Halliger, who is an infectious disease expert in Denmark.
1:31.1	Sophie's a friend of the show, Anne Plannard, and asked me to take a look at a policy forum piece that is co-authored by Didier Rauled. That's right, Didier Rauled, the man,
1:37.5	the myth, the legend. He put hydroxychloroquine on the map. And only later did we learn that hydroxychloroquine was completely mistaken as every single randomized trial to date finds that
1:43.5	it is staggeringly negative and has
1:45.9	no benefit for COVID-19. But that doesn't stop him from doubling down. First, I think in all
1:53.4	seriousness, we should acknowledge that this gentleman did a major disservice in the middle of a
1:58.2	pandemic. He displayed an animosity for randomized controlled
2:02.9	trials and a propensity to hype uncontrolled quasi-experimental data, if you'll call it that,
2:11.0	in his 1,000-person uncontrolled study. And he promulgated and pushed the use of hydroxychloroquine and got a lot of people
2:19.0	to use it. And in retrospect, all those people probably took something that had no benefit.
2:28.0	And he wasted a lot of time, and he squandered the most precious resource there is in a pandemic or in any medical
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.